Invariant Vα14 natural killer T (NKT) cells, characterized by the expression of a single invariant T cell receptor (TCR) α chain encoded by rearranged Trav11 (Vα14)-Traj18 (Jα18) gene segments in mice, and TRAV10 (Vα24)-TRAJ18 (Jα18) in humans, mediate adjuvant effects to activate various effector cell types in both innate and adaptive immune systems that facilitates the potent antitumor effects. It was recently reported that the Jα18-deficient mouse described by our group in 1997 harbors perturbed TCRα repertoire, which raised concerns regarding the validity of some of the experimental conclusions that have been made using this mouse line. To resolve this concern, we generated a novel Traj18-deficient mouse line by specifically targeting the Traj18 gene segment using Cre-Lox approach. Here we showed the newly generated Traj18-deficient mouse has, apart from the absence of Traj18, an undisturbed TCRα chain repertoire by using next generation sequencing and by detecting normal generation of Vα19Jα33 expressing mucosal associated invariant T cells, whose development was abrogated in the originally described Jα18-KO mice. We also demonstrated here the definitive requirement for NKT cells in the protection against tumors and their potent adjuvant effects on antigen-specific CD8 T cells.
Introduction
Invariant Vα14 natural killer T (NKT) cells are a unique lymphocyte subset characterized by the expression of a single invariant T cell receptor (TCR) α chain encoded by rearranged Trav11 (Vα14)-Traj18 (Jα18) gene segments in mice, and TRAV10 (Vα24)-TRAJ18 (Jα18) in humans. Both human and mouse NKT cells recognize glycolipid ligands, such as α-galactosylceramide (αGalCer), presented by the monomorphic major histocompatibility complex (MHC)-like CD1d molecule. NKT cells mediate many important immune regulatory functions, such as protection against pathogens and tumors, maintenance of transplantation tolerance, prevention of autoimmune disease development, and regulation of allergic responses. One of most well-studied and important features of NKT cells is their adjuvant activity, which can induce activation of both adaptive and innate arms of the immune response. For example, in the cancer setting NKT-activated adaptive CD8 T and innate NK effector cells can kill MHC-positive and MHC-negative tumor cells, respectively, thus effectively eliminating the tumor [1, 2] .
Many investigators have used the originally established Jα18-deficient mice, described by our group back in 1997, which paved the way to understanding the functional roles of NKT cells in various experimental settings [3] . However, a recently published correspondence described a perturbed TCRα repertoire in these mice due to suppressed transcription of Traj gene segments upstream of Traj18 [4] . This has raised concerns regarding the validity of some of the experimental conclusions that have been made using this mouse line.
In this study, we established a novel Traj18-deficient mouse line lacking specifically invariant NKT cell lineage that could be used as an undisputed mouse model for future investigations in the NKT cell field, and also validated cardinal features of NKT cells related with potent tumor rejection and adjuvant effects on antigen-specific adaptive immunity.
Materials and Methods

Generation of Traj18-deficient mice
A Traj18 region targeting vector was constructed as shown in Fig 1, and then transduced into B6JN/1 mouse embryonic stem cells, derived from a (C57BL6/J Jcl) x (C57BL6/N Jcl) embryo, that were established at the RIKEN IMS animal facility, and were further selected using conventional methods. The FRT-flanked neomycin cassette was removed by mating of chimeric mice to CAG-FLP recombinase transgenic mice, and the loxP-flanked Traj18 region was subsequently deleted by breeding to CAG-Cre recombinase transgenic mice. The resultant mice were mated to derive homozygous Traj18-deficient mice.
Mice
Wild-type (WT) C57BL/6 (B6) mice were purchased from Charles River Laboratories, Jα18 -/-and Cd1d1
Cd1d2
-/-mouse lines were described [3, 5] . Mice were maintained in the animal facility of RIKEN IMS under specific pathogen-free conditions and were used at 8-10 weeks of age. All animal experiments were approved by RIKEN Animal Care and Use Committee.
Cell preparation and flow cytometry FITC, PE, PerCP-Cy5.5, PE-Cy7, APC, or BV421 conjugated mAbs specific for B220 (RA3-6B2), CD3ε (145-2C11), CD4 (GK1.5), CD8α (53-6.7), TCRβ (H57-597) were purchased from BD Biosciences or BioLegend or eBioscience. Thymocytes, splenocytes and liver mononuclear cells were prepared and stained with αGalCer/CD1d dimers as described [6, 7] . Lungs were prepared as described [8] . Cell staining was performed after blocking with anti-FcR (2.4G2). Forward light-scatter gating and 7-AAD staining were used to gate out dead cells. Samples were analyzed using FACSCanto or FACSAria instruments (BD Biosciences), and data were analyzed with FlowJo (Tree Star).
Systemic activation of NKT cells with αGalCer
Two micrograms of αGalCer were injected into the tail veins of WT or Traj18 -/-mice or
Cd1d1
-/-Cd1d2 -/-mice. Blood serum was collected at 3 or 24 h post-injection and cytokine levels were measured using a cytokine bead assay according to the manufacturer's instructions (BD Biosciences). Data were acquired using FACS Canto flow cytometer (BD Biosciences), and analyzed with FCAP Array™ software (Soft Flow).
TCR sequencing
CD4
+ CD8 + thymocytes from WT or Traj18-deficient mice were sorted on a FACS Aria cell sorter (BD Biosciences) with post-sort purity above 99%. Cells were lysed and RNA was extracted with RNeasy kit (Qiagen). cDNA was prepared with Superscript First-Strand SuperMix (Life Technologies). The following primers with Illumina adaptor sequences at the 5' ends were used to amplify the Trav11-Trac transcripts (Trav11 sense, 5'-GTCCTCAGTCCCTGGTTGTC-3' and Trac anti-sense, 5'-AGGGTGCTGTCCTGAGACCGA-3') using a KAPA HiFi high fidelity PCR mix (Kapa Biosystems). PCR products were purified and sequenced on a MiSeq system with a MiSeq Reagent Kit v3, 600 cycles (Illumina). Mouse TCR Jα regions were analyzed using IMGT/HighV-QUEST from the IMGT (international ImMunoGeneTics information system) database [9] .
B16 melanoma metastasis model
Mice were anesthetized and the spleen was surgically removed on day 0 after intrasplenic inoculation of B16 melanoma (5×10 5 ) cells. Two days after inoculation of B16, mice were injected intravenously with αGalCer-pulsed bone marrow derived DCs (5×10 5 ). The mice were sacrificed on day 14 after B16 inoculation, and the liver was visually evaluated for B16 metastases. Novel Traj18-Deficient Mice Lacking Vα14 Natural Killer T Cells αGalCer-induced adjuvant activity on OVA-specific CD8 T cells
To identify OVA-specific T cells expanded upon NKT stimulation in vivo, splenocytes were prepared according to a published report [10] with some minor modifications. In brief, splenocytes pulsed with OVA peptide (Worthington Biochemical) were administered intravenously with 2 μg of αGalCer into the tail veins of recipient mice. Seven days later the mice were sacrificed and splenocytes were directly assessed for the presence of OVA-specific CD8 T cells using anti-CD3, CD8 (BD Biosciences) and T-Select H-2Kb OVA Tetramer-SIINFEKL-APC (MBL), or were primed in vitro with or without 1 μM OVA 257-264 peptide (SIINFEKL) (Abbiotec) for 6 h in the presence of GolgiPlug (BD Biosciences). The cells were then stained with cell-surface markers, fixed with Cytofix/Cytoperm Plus permeabilization kit (BD Biosciences), and stained with an anti-IFN-γ mAb (BD Biosciences).
Real-time quantitative RT-PCR
Total RNA was prepared from sorted lung αGC/CD1d 
Statistical analysis
Statistical analyses were performed using Prism 6.0 software (GraphPad). Two-tailed unpaired t test was used to compare two groups. P-values less than 0.05 were considered statistically significant.
Results and Discussion
Generation of novel Traj18-deficient mice lacking Vα14 NKT cells
In the original Jα18-deficient mouse line the PGK-neo r selection cassette from the targeting vector was retained in the genome, prompting Bedel, et al. to speculate that the neo transcription was causing the abnormal usage of Traj gene segments [3, 4] . To circumvent this problem, in the new mouse strain we used Cre-and Flp-mediated site-specific recombinase technologies to specifically and cleanly delete the Traj18 gene segment (Fig 1) . The resultant mouse line, termed Traj18 -/-, was totally devoid of NKT cells in the thymus as well as in the spleen and liver, as revealed by staining with αGalCer-loaded CD1d dimer staining, where unloaded CD1d dimer staining served to exclude the background staining (Fig 2A) . Moreover, the intravenous injection of the NKT cell-specific agonist ligand αGalCer demonstrated the absence of functional NKT cells in Traj18 -/-mice, assessed by increased levels of IL-4 and IFN-γ, which were only detected in wild-type (WT) mice at 3 h and 24 h post-injection, respectively, but were undetectable in Traj18 -/-mice, or in Cd1d1
The latter mouse is another widely used model that has intact TCRα chain gene rearrangements but is deficient in both invariant and non-invariant NKT cells due to absence of the CD1d positive selector molecule [5] . -/-Cd1d2 -/-or Traj18 -/-mice were injected intravenously with 2 μg of αGalCer and blood plasma were collected after either 3 h and 24 h, and IFN-γ and IL-4 concentrations were measured using cytokine beads assay. Bars depict mean ± SEM of n = 3 mice per genotype analyzed. Data are representative of three experiments. (Fig 3) .
Normal development of MAIT cells with invariant Vα19Jα33 TCR α chain rearrangement in Traj18-deficient mice
To provide an additional proof of an undisturbed development of T cell lineages in Traj18
-/-mice, we assessed mucosal-associated invariant T (MAIT) cells representing a well-characterized MR1-restricted T cell lineage that uses invariant Vα19Jα33 in mice, and Vα7.2 joined to either Jα33 or Jα12 or Jα20 in humans [11] . It has been previously reported that the highest frequency of MAIT cells in B6 mice was detected in lung with the MR1-tetramer staining [12] . To this end, we sorted αGalCer/CD1d -TCRβ + lung T lymphocytes from WT or Traj18 -/-mice as well as from previously generated Jα18 -/-mice [3] that was reported to have a defective transcription of Traj gene segments upstream of Traj18 [4] (Fig 4A) , and assessed expressions of the invariant Vα19Jα33 TCRα chain encoded by Trav1 and Traj33 using realtime quantitative RT-PCR. Results clearly demonstrated the normal development of MAIT cells in Traj18 -/-mice as compared with control WT mice (Fig 4B) , while Jα18 -/-mice lacked expression of Trav1-Traj33, indicating defective development of MAIT cells in the latter mouse line, which was in agreement with the previous report [4] . These results evidenced the normal development of T cells except for the absence of NKT cells in the newly generated Traj18 -/-mouse line. Failure to demonstrate NKT cell-mediated adjuvant activity on OVAspecific CD8 T cells in Traj18-deficient mice
In order to confirm the adjuvant activity of NKT cells in the induction of antigen-specific CD8 T cells that presumably kill MHC-positive tumors, we assessed the frequency of such cytotoxic CD8 T cells upon administration of αGalCer into WT or Traj18 -/-mice. We observed significantly increased frequencies and numbers of OVA-specific CD8 T cells in WT but not in Traj18 -/-mice ( Fig 5A, 5B and 5C) as well as clonotypic expansion and activation of IFN-γ producing antigen-specific CD8 T cells in WT but not in Traj18 -/-mice ( Fig 5D, 5E and 5F). These data provide evidence proving the potent adjuvant effects of αGalCer activated NKT cells in the induction of antigen-specific CD8 T cells.
Failure to demonstrate NKT cell-mediated anti-tumor effects in Traj18-deficient mice
Based on mouse and human studies, NKT cell-targeted adjuvant cell therapy was approved by the Japanese government for advanced non-small cell lung cancer in 2011, head and neck tumors in 2013, and post surgery stage IIA-IIIA non-small cell lung cancer in 2014 [13] . Therefore it was imperative to investigate the role of NKT cells in tumor rejection using the newly generated Traj18 -/-mice.
To this end, we used a B16 melanoma liver metastasis model, where mice bearing metastatic melanoma nodules in the liver were treated by intravenous administration of αGalCer-pulsed dendritic cells (αGalCer-DC) as described previously [14] . This NKT cell-targeting immunotherapy resulted in the complete eradication of melanoma metastasis in WT but not in Traj18 -/-mice. Indeed the tumor growth in αGalCer-DC treated Traj18 -/-mice was similar to that in the vehicle-treated WT and Traj18 -/-mouse groups, demonstrating the absolute requirement for αGalCer-DC activated NKT cells in tumor rejection (Fig 6A and 6B) . Collectively, our present study clearly demonstrated the protective role of NKT cells against tumors by using the newly generated Traj18 -/-mice that specifically lack the NKT cell lineage and, apart from the absence of Traj18, have an undisturbed TCRα chain repertoire. Of note, while our manuscript was in preparation, another Traj18-deficient mouse line was reported, where the authors demonstrated a role of NKT cells in airway inflammation and resistance using OVA-induced and cockroach antigen-induced pulmonary inflammation models [15] . Thus, our results together with those from the Kronenberg group confirm the definitive requirement for NKT cells in both protection against tumors and regulation of allergic responses, using independently generated Traj18 -/-mouse strains with essentially normal TCR repertoires. The authors hope that both mouse lines will be useful for future investigations aimed in specifically assessing the role of NKT cells in various experimental settings. 
